Unaudited Financial Results of the Company for the quarter ended December 31, 2025.
ABBOTINDIA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Abbott India reported Q3 FY26 revenue from operations of ₹1,724.04 Cr, up about 6.8% from ₹1,614.28 Cr in Q3 FY25. For nine months ended December 31, 2025, revenue grew to ₹5,219.54 Cr versus ₹4,804.56 Cr last year, an 8.6% increase. Net profit for the quarter was ₹375.96 Cr (vs ₹360.78 Cr, up ~4.2%), and for nine months it stood at ₹1,157.09 Cr (vs ₹1,047.40 Cr, up ~10.5%). Basic EPS for the quarter was ₹176.92. The company recognized a one-time incremental employee benefit cost of ₹35.10 Cr due to the New Labour Codes effective November 21, 2025, which pushed up employee expenses sharply. The statutory auditors (Walker Chandiok & Co LLP) issued an unqualified limited review report.
Modest revenue and profit growth with margins slightly compressed in the quarter due to a one-time labour code charge; underlying business remains steady with double-digit profit growth on a nine-month basis, broadly neutral to mildly positive for shareholders.